Mortality Among HIV Patients in ISRAEL: A 20-Year Retrospective Cohort

TL;DR

This study examines 20 years of HIV patient mortality in Israel, finding that while overall mortality decreased, non-AIDS-related deaths increased.

Contribution

The study provides updated insights into mortality trends and risk factors for HIV patients in Israel during the modern ART era.

Findings

Mortality rates decreased from 2.12% in 2005–2008 to 0.71% in 2018–2021.

Non-AIDS-related deaths increased from 25% in 2001–2002 to 75% in 2019–2021.

Low CD4, high viral load, non-MSM transmission, and non-compliance were significant risk factors for mortality.

Abstract

The objectives of our study were to determine the mortality rates, causes, and risk factors of people living with HIV in the modern antiretroviral therapy era, in a major HIV center in Israel. We retrospectively collected data from 1547 patients treated during 2001–2021. We used the Shapiro–Wilk test, Fisher’s exact test, Student’s t test, and chi-square to compare between patients who died and those who did not, and between patients who died from AIDS-related and non-AIDS-related causes. In total, 206 (13.3%) patients died. The causes of death were AIDS-defining diseases (33.5%), cardiovascular diseases (21.8%), non-AIDS infections (16%), and hepatic disorders (7%). The annual mortality rate was 1.31 ± 0.3%. Despite an increase in age (35 ± 13.2 in 2001, 49 ± 13.6 years in 2021; p < 0.001), the mortality rate decreased (2.12% during 2005–2008, 0.71% during 2018–2021; p = 0.0001). AIDS-defining diseases caused 75% of deaths during 2001–2002, and only 25% during 2019–2021. The proportion of cardiovascular deaths increased (8.3% in 2001–2003, 33.3% in 2019–2021; p < 0.001). Low CD4 and high viral load at diagnosis, male gender, non-MSM HIV acquisition (heterosexual transmission and people who inject drugs), and inability to achieve viral suppression because of non-compliance were risk factors for mortality. Mortality rates decreased during 2001–2021; however, the proportion of non-AIDS deaths increased. Early cardiovascular comorbidity screening and targeted adherence interventions in non-MSM populations and in patients with low CD4 are needed.

Figures